Table 3.
Meta-analysis of laboratory data for IgAN recurence.
| Laboratory parameters | No. of studies | n | Heterogeneity | Effects model | ES | ES [95% CI] | Z | P | |
|---|---|---|---|---|---|---|---|---|---|
| I² | P | ||||||||
| IgG (g/L) | |||||||||
| Baseline | 3 | 268 | 79.70% | 0.0073 | R | MD | 1.48 [-0.19, 3.16] | 1.74 | 0.0827 |
| IgA (mg/L) | |||||||||
| Baseline | 5 | 615 | 83.20% | < 0.0001 | R | MD | 0.48 [-0.10, 1.05] | 1.63 | 0.1033 |
| 6 month | 2 | 225 | 88.40% | 0.0033 | R | MD | 0.19 [-0.83, 1.20] | 0.36 | 0.7197 |
| 1 year | 3 | 561 | 81.30% | 0.0048 | R | MD | 0.32 [-0.28, 0.92] | 1.04 | 0.2997 |
| Gd-IgA1 | |||||||||
| Baseline | 5 | 400 | 2.70% | 0.3911 | F | SMD | 0.05 [-0.17, 0.27] | 0.44 | 0.6634 |
| Hematuria | |||||||||
| 1 year | 3 | 232 | 89.50% | 0.0021 | R | SMD | 1.29 [0.10, 2.47] | 2.13 | 0.0328 |
| 3 year | 3 | 232 | 97.90% | < 0.0001 | R | SMD | 1.94 [-0.65, 4.54] | 1.47 | 0.1425 |
| 5 year | 2 | 183 | 99.30% | < 0.0001 | R | SMD | 5.09 [-3.10, 13.28] | 1.22 | 0.2231 |
| Post KT * | 6 | 646 | 77.20% | 0.0005 | R | RR | 3.27 [1.63, 6.55] | 3.33 | 0.0009 |
| Proteinuria | |||||||||
| 6 month | 2 | 173 | 67.50% | 0.0795 | R | SMD | 0.33 [-0.31, 0.96] | 1.01 | 0.3128 |
| 1 year | 5 | 477 | 33.40% | 0.1989 | F | SMD | 0.37 [0.17, 0.58] | 3.52 | 0.0004 |
| 3 year | 2 | 197 | 0.00% | 0.9672 | F | SMD | 1.76 [1.41, 2.11] | 9.78 | < 0.0001 |
| 5 year * | 2 | 355 | 58.50% | 0.1208 | R | RR | 2.19 [1.12, 4.31] | 2.28 | 0.0227 |
| Time at biopsy | 4 | 182 | 0.00% | 0.6860 | F | SMD | 0.22 [-0.08, 0.53] | 1.46 | 0.1431 |
| Time at biopsy * | 2 | 334 | 74.90% | 0.0461 | R | RR | 3.91 [0.88, 17.25] | 1.80 | 0.0722 |
| Last follow up | 7 | 587 | 85.30% | < 0.0001 | R | SMD | 1.25 [0.55, 1.94] | 3.49 | 0.0005 |
| eGFR (ml/min/1.73m2) | |||||||||
| Baseline | 2 | 197 | 0.00% | 0.8518 | F | MD | -0.05 [-2.28, 2.18] | -0.05 | 0.9626 |
| 6 month | 5 | 708 | 29.70% | 0.2233 | F | MD | 0.05 [-2.23, 2.33] | 0.04 | 0.966 |
| 2 year | 2 | 307 | 95.10% | < 0.0001 | R | MD | -14.37 [-37.20, 8.46] | -1.23 | 0.2173 |
| 3 year | 3 | 608 | 98.90% | < 0.0001 | R | MD | -11.31 [-30.18, 7.57] | -1.17 | 0.2403 |
| 5 year | 3 | 608 | 99.30% | < 0.0001 | R | MD | 12.87 [-38.14, 12.40] | -1.00 | 0.3181 |
| Last follow up | 4 | 410 | 0.00% | 0.9340 | F | MD | -12.37 [-17.25, -7.49] | -4.97 | < 0.0001 |
| Serum creatinine (mg/dL) | |||||||||
| Baseline | 4 | 358 | 83.80% | 0.0003 | R | MD | -0.05 [-0.18, 0.08] | -0.76 | 0.4490 |
| 6 month | 2 | 173 | 92.30% | 0.0003 | R | MD | -0.23 [-0.78, 0.33] | -0.80 | 0.4240 |
| 1 year | 7 | 469 | 0.00% | 0.7372 | F | MD | -0.10 [-0.30, 0.10] | -1.00 | 0.3186 |
| 3 year | 3 | 253 | 89.30% | < 0.0001 | R | MD | 0.58 [-0.14, 1.30] | 1.57 | 0.1156 |
| 5 year | 4 | 307 | 99.80% | < 0.0001 | R | MD | 1.01 [-0.55, 2.57] | 1.27 | 0.2050 |
| Last follow up | 8 | 562 | 37.90% | 0.1269 | F | MD | 0.49 [0.35, 0.64] | 6.60 | < 0.0001 |
IgAN, immunoglobulin A nephropathy; ES, effect size; CI, confidence interval; R, random effects model; F, fixed effect model; MD, mean difference; SMD, standardized mean difference; RR, risk ratio; IgG, immunoglobulin G; IgA, immunoglobulin A; Gd-IgA1, galactose deficiency IgA1; KT, kidney transplantation; eGFR, estimated glomerular filtration rate.
*dichotomous variables.